New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Objective: To evaluate the effect of hybrid-closed loop Control-IQ technology (Control-IQ) in randomized controlled trials (RCTs) in subgroups based on baseline characteristics such as race/ethnicity, socioeconomic status (SES), prestudy insulin delivery modality (pump or multiple daily injections), and baseline glycemic control. Methods: Data were pooled and analyzed from 3 RCTs comparing Control-IQ to a Control group using continuous glucose monitoring in 369 participants with type 1 diabetes (T1D) from age 2 to 72 years old. Results: Time in range 70-180?mg/dL (TIR) in the Control-IQ group (n?=?256) increased from 57%?±?17% at baseline to 70%?±?11% during follow-up, and in the Control group (n?=?113) was 56%?±?15% and 57%?±?14%, respectively (adjusted treatment group difference?=?11.5%, 95% confidence interval +9.7% to +13.2%, P?
View details for DOI 10.1089/dia.2022.0558
View details for PubMedID 37067353